Literature DB >> 21258256

Thoracoscopic assessment of pleural tumor burden in patients with malignant pleural effusion: prognostic and therapeutic implications.

Lama Sakr1, Fabien Maldonado, Laurent Greillier, Hervé Dutau, Anderson Loundou, Philippe Astoul.   

Abstract

BACKGROUND: Malignant pleural effusion (MPE) is encountered at an advanced stage of disease progression and often heralds a poor prognosis. The most reliable predictive factor of survival in such patients is the primary tumor. Thoracoscopy is often performed for accurate diagnosis and/or thoracoscopic talc insufflation as a therapeutic modality. It remains unknown whether pleural tumor burden, as visualized on thoracoscopy, has potential prognostic value. The objective of this study was to determine the prognostic accuracy of pleural tumor extent and localization (parietal, visceral, or diaphragmatic involvement), as assessed during medical thoracoscopy.
METHODS: Medical records of all patients who underwent thoracoscopy for suspicion of MPE between 2001 and 2008 at a tertiary care referral hospital were reviewed. Patients were included if pleural metastatic invasion was confirmed on tissue biopsy and survival status ascertained.
RESULTS: Four hundred twenty-one patients underwent diagnostic or therapeutic medical thoracoscopy at our referral center. Among them, 122 had confirmed metastatic pleural spread, but survival data were lacking in 15. Primary tumor consisted of non-mall cell lung cancer in 56, breast cancer in 23, melanoma in eight, and other malignancies in 20. Median survival of the entire population was 9.4 months. On univariate analysis, the following variables were significantly associated with reduced median overall survival: pleural metastatic melanoma, age less than 60 years, bloody MPE, extensive pleural adhesions, and widespread visceral pleural nodules (p < 0.05). On multivariate analysis, only melanoma as a primary tumor, pleural fluid appearance and extent of pleural adhesions remained independent and significant predictors of survival.
CONCLUSION: No significant association was found between the extent or localization of pleural tumor burden and overall survival.

Entities:  

Mesh:

Year:  2011        PMID: 21258256     DOI: 10.1097/JTO.0b013e318208c7c1

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  6 in total

Review 1.  Malignant pleural effusion: tumor-host interactions unleashed.

Authors:  Georgios T Stathopoulos; Ioannis Kalomenidis
Journal:  Am J Respir Crit Care Med       Date:  2012-05-31       Impact factor: 21.405

2.  Diagnostic value and safety of medical thoracoscopy for pleural effusion of different causes.

Authors:  Xiao-Ting Liu; Xi-Lin Dong; Yu Zhang; Ping Fang; Hong-Yang Shi; Zong-Juan Ming
Journal:  World J Clin Cases       Date:  2022-04-06       Impact factor: 1.534

3.  Malignant Pleural Effusion and ascites Induce Epithelial-Mesenchymal Transition and Cancer Stem-like Cell Properties via the Vascular Endothelial Growth Factor (VEGF)/Phosphatidylinositol 3-Kinase (PI3K)/Akt/Mechanistic Target of Rapamycin (mTOR) Pathway.

Authors:  Tao Yin; Guoping Wang; Sisi He; Guobo Shen; Chao Su; Yan Zhang; Xiawei Wei; Tinghong Ye; Ling Li; Shengyong Yang; Dan Li; Fuchun Guo; Zeming Mo; Yang Wan; Ping Ai; Xiaojuan Zhou; Yantong Liu; Yongsheng Wang; Yuquan Wei
Journal:  J Biol Chem       Date:  2016-10-18       Impact factor: 5.157

4.  Good response of malignant pleural effusion from carcinoma of unknown primary site to the anti-tuberculosis therapy: a case report.

Authors:  Qihua Gu; Chengping Hu; Jingjing Qu
Journal:  Int J Clin Exp Pathol       Date:  2013-04-15

5.  [Therapeutical effects of pleural injecting recombinant human endostain to 
malignant pleural effusion nude mice model].

Authors:  Ming Zhou; Min Li; Huaping Yang; Chengping Hu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2015-05

6.  Predictors of survival in non-small cell lung cancer patients with pleural effusion undergoing thoracoscopy.

Authors:  Li-Xu Xie; Xing-Guang Wang; Wen-Jie You; Xiao-Bin Ma; Yong-Gang Wang; Ting-Ting Liu; Shu-Juan Jiang
Journal:  Thorac Cancer       Date:  2019-05-15       Impact factor: 3.500

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.